Related Experiment Video
Updated: Jun 12, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Virtual screening, molecular docking, and molecular dynamics simulation studies on the hypoglycemic function of oat
Zhongfu Tan1, Jiayang Song1, Ting Zhang1
1Department of Pharmacy, Cangxi People's Hospital, Guangyuan, 628499, PR China.
Oat peptides show potential for blood sugar control. Research identified specific oat peptides that stably bind to DPP4, suggesting their use in developing new diabetes inhibitors.
Area of Science:
- Nutritional biochemistry
- Computational drug discovery
Background:
- Oat peptides are known for their potential health benefits, including blood sugar regulation.
- Dipeptidyl peptidase-4 (DPP4) is a key target for type 2 diabetes treatment.
Purpose of the Study:
- To identify and evaluate oat peptides that can inhibit DPP4 activity.
- To provide a molecular basis for developing oat peptide-based DPP4 inhibitors.
Main Methods:
- Literature review and database construction of oat peptides.
- Virtual screening of oat peptides against the DPP4 protein.
- Molecular dynamics simulations and binding free energy calculations.
Main Results:
- A database of oat peptides was created and screened against DPP4.
- Six peptides showed stable binding to DPP4 after virtual screening.
- Two oat peptides exhibited strong affinity for DPP4, indicating potential as lead compounds.
Conclusions:
- Oat peptides can effectively bind to DPP4, offering a novel therapeutic avenue.
- The identified lead oat peptides can guide the design of new DPP4 inhibitors for diabetes management.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides